ARGX - ARGENX SE

749.56
0.840   0.112%

Share volume: 338,139
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$748.72
0.84
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-0.95%
1 Month
-8.62%
3 Months
-16.82%
6 Months
-0.16%
1 Year
17.76%
2 Year
20.31%
Key data
Stock price
$749.56
P/E Ratio 
N/A
DAY RANGE
$741.40 - $757.70
EPS 
N/A
52 WEEK RANGE
$510.06 - $934.62
52 WEEK CHANGE
$22.24
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$415,896
AVERAGE 30 VOLUME 
$376,648
Company detail
CEO: Tim v. Hauwermeiren
Region: US
Website: argenx.com
Employees: 650
IPO year: 2017
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.

Recent news